TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

PLoS Pathogens

Volumn 12, Issue 1, 2016, Pages

  Chew, Glen M ^a   Fujita, Tsuyoshi ^a,b   Webb, Gabriela M ^c,d   Burwitz, Benjamin J ^c,d   Wu, Helen L ^c,d   Reed, Jason S ^c,d   Hammond, Katherine B ^c,d   Clayton, Kiera L ^e   Ishii, Naoto ^b   Abdel Mohsen, Mohamed ^f   Liegler, Teri ^f   Mitchell, Brooks I ^a   Hecht, Frederick M ^f   Ostrowski, Mario ^e   Shikuma, Cecilia M ^a   Hansen, Scott G ^c,d   Maurer, Mark ^g   Korman, Alan J ^g   Deeks, Steven G ^f   Sacha, Jonah B ^c,d   Ndhlovu, Lishomwa C ^a   more..

^a UNIVERSITY OF HAWAII   (United States)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Bristol Myers Squibb   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOMEGALOVIRUS ANTIGEN PP65; GAG PROTEIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 2; KI 67 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNORECEPTOR WITH IMMUNOGLOBULIN AND ITIM DOMAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; TIGIT PROTEIN, HUMAN; VIRUS DNA; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; EFFECTOR CELL; EXHAUSTED T CELL; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS INFECTION; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CELL SEPARATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; RHESUS MONKEY;

ANIMALS; ANTIGENS, CD274; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; DISEASE PROGRESSION; DNA, VIRAL; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MACACA MULATTA; RECEPTORS, IMMUNOLOGIC; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 84956803081     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005349     Document Type: Article

References (63)

1. Wherry EJ, (2011) T cell exhaustion. Nat Immunol 12: 492–499. 21739672
2. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354. 16921384
3. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, et al. (2012) PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 122: 1712–1716. doi: 10.1172/JCI60612 22523065
4. Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, et al. (2007) SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 110: 928–936. 17440051
5. Porichis F, Kaufmann DE, (2012) Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep 9: 81–90. doi: 10.1007/s11904-011-0106-4 22198819
6. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, et al. (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12: 1198–1202. 16917489
7. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, et al. (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206–210. doi: 10.1038/nature07662 19078956
8. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205: 2763–2779. doi: 10.1084/jem.20081398 19001139
9. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, et al. (2010) HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 40: 2493–2505. doi: 10.1002/eji.201040340 20623550
10. Kaufmann DE, Walker BD, (2009) PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 182: 5891–5897. doi: 10.4049/jimmunol.0803771 19414738
11. Vigano S, Banga R, Bellanger F, Pellaton C, Farina A, et al. (2014) CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression. PLoS Pathog 10: e1004380. doi: 10.1371/journal.ppat.1004380 25255144
12. Tian X, Zhang A, Qiu C, Wang W, Yang Y, et al. (2015) The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects. J Immunol 194: 3873–3882. doi: 10.4049/jimmunol.1402176 25780040
13. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, et al. (2013) A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8: e63818. doi: 10.1371/journal.pone.0063818 23717490
14. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, et al. (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515: 572–576. doi: 10.1038/nature14001 25428506
15. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, et al. (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558–562. doi: 10.1038/nature13904 25428503
16. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134–144. doi: 10.1056/NEJMoa1305133 23724846
17. Chen DS, Mellman I, (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39: 1–10. doi: 10.1016/j.immuni.2013.07.012 23890059
18. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, et al. (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26: 923–937. doi: 10.1016/j.ccell.2014.10.018 25465800
19. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, et al. (2015) TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest.
20. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, et al. (2011) Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood 117: 4805–4815. doi: 10.1182/blood-2010-11-317297 21398582
21. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G, (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73: 3591–3603. doi: 10.1158/0008-5472.CAN-12-4100 23633484
22. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, et al. (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10: 29–37. doi: 10.1038/ni.1679 19043418
23. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, et al. (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10: 48–57. doi: 10.1038/ni.1674 19011627
24. Stengel KF, Harden-Bowles K, Yu X, Rouge L, Yin J, et al. (2012) Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A 109: 5399–5404. doi: 10.1073/pnas.1120606109 22421438
25. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, et al. (2011) Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 186: 1338–1342. doi: 10.4049/jimmunol.1003081 21199897
26. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, et al. (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106: 17858–17863. doi: 10.1073/pnas.0903474106 19815499
27. Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, et al. (2009) A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol 39: 695–703. doi: 10.1002/eji.200839116 19197944
28. Martinet L, Smyth MJ, (2015) Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 15: 243–254. doi: 10.1038/nri3799 25743219
29. Foks AC, Ran IA, Frodermann V, Bot I, van Santbrink PJ, et al. (2013) Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development. PLoS One 8: e83134. doi: 10.1371/journal.pone.0083134 24376654
30. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, et al. (2014) Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40: 569–581. doi: 10.1016/j.immuni.2014.02.012 24745333
31. Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA, (2012) The TIGIT/CD226 axis regulates human T cell function. J Immunol 188: 3869–3875. doi: 10.4049/jimmunol.1103627 22427644
32. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, et al. (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8: 379–385. 11927944
33. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, et al. (2004) Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2: E20. 14966528
34. Barbour JD, Ndhlovu LC, Xuan Tan Q, Ho T, Epling L, et al. (2009) High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication. PLoS One 4: e4408. doi: 10.1371/journal.pone.0004408 19198651
35. Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, et al. (2012) Antigen-independent induction of Tim-3 expression on human T cells by the common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol 188: 3745–3756. doi: 10.4049/jimmunol.1102609 22422881
36. Sun Y, Schmitz JE, Acierno PM, Santra S, Subbramanian RA, et al. (2005) Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. J Immunol 174: 4753–4760. 15814700
37. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, et al. (2003) HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198: 1909–1922. 14676302
38. Fujita T, Burwitz BJ, Chew GM, Reed JS, Pathak R, et al. (2014) Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques. J Immunol 193: 5576–5583. doi: 10.4049/jimmunol.1400961 25348621
39. Hosking MP, Flynn CT, Botten J, Whitton JL, (2013) CD8+ memory T cells appear exhausted within hours of acute virus infection. J Immunol 191: 4211–4222. doi: 10.4049/jimmunol.1300920 24026080
40. Rekik R, Belhadj Hmida N, Ben Hmid A, Zamali I, Kammoun N, et al. (2014) PD-1 induction through TCR activation is partially regulated by endogenous TGF-beta. Cell Mol Immunol.
41. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, et al. (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181: 6738–6746. 18981091
42. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, et al. (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41: 1053–1056. 16142675
43. Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, et al. (2014) Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis 209: 931–939. doi: 10.1093/infdis/jit581 24185941
44. Okulicz JF, Lambotte O, (2011) Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS 6: 163–168. doi: 10.1097/COH.0b013e328344f35e 21502920
45. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, et al. (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197: 126–133. doi: 10.1086/524143 18171295
46. Lopez M, Soriano V, Peris-Pertusa A, Rallon N, Restrepo C, et al. (2011) Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. AIDS Res Hum Retroviruses 27: 157–165. doi: 10.1089/aid.2010.0107 20964478
47. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, et al. (2009) Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 200: 984–990. doi: 10.1086/605446 19656066
48. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, et al. (2009) Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 83: 329–335. doi: 10.1128/JVI.01763-08 18945778
49. Crowell TA, Gebo KA, Blankson JN, Korthuis PT, Yehia BR, et al. (2014) Hospitalization Rates and Reasons among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. J Infect Dis.
50. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454. doi: 10.1056/NEJMoa1200690 22658127
51. Pasternak AO, Lukashov VV, Berkhout B, (2013) Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 10: 41. doi: 10.1186/1742-4690-10-41 23587031
52. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482–485. doi: 10.1038/nature11286 22837004
53. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, et al. (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10: e1004071. doi: 10.1371/journal.ppat.1004071 24722454
54. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, et al. (2013) Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9: 993–1001. doi: 10.4161/hv.23800 23370291
55. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491–501. doi: 10.1016/j.immuni.2012.01.014 22406268
56. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, et al. (2015) Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517: 381–385. doi: 10.1038/nature14053 25561180
57. Deeks SG, (2012) HIV: Shock and kill. Nature 487: 439–440. doi: 10.1038/487439a 22836995
58. Clayton KL, Douglas-Vail MB, Rahman AK, Medcalf KE, Xie IY, et al. (2015) Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8+ T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression. J Virol 89: 3723–3736. doi: 10.1128/JVI.00006-15 25609823
59. Watters MR, Poff PW, Shiramizu BT, Holck PS, Fast KM, et al. (2004) Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 62: 1378–1383. 15111677
60. Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M, (2007) Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol 13: 210–224. 17613711
61. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, et al. (1994) Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368: 856–859. 8159246
62. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, et al. (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14: 845–851. 9631008
63. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, et al. (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 15: 289–302. 11520463